Achievement of Goal Resting Heart Rate on B-blockers in Patients With Stable Angina and Hypertension (Athena)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01321242 |
Recruitment Status
:
Completed
First Posted
: March 23, 2011
Last Update Posted
: June 1, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Stable Angina Hypertension |
Study Type : | Observational |
Actual Enrollment : | 400 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Observational Non-interventional Study - Epidemiological Survey "AchievemenT of Goal Resting HEart Rate on Beta-blockers in Patients With Stable angiNA and Hypertension in Routine Practice" |
Study Start Date : | April 2011 |
Actual Primary Completion Date : | August 2011 |
Actual Study Completion Date : | August 2011 |

Group/Cohort |
---|
achieving resting HR goals
Patient population will be comprised of typical for cardiological practice sample of patients with Coronary Heart Disease and arterial hypertension administered beta-blockers, subjects achieving resting HR goals, according to ACC/AHA/ACP-ASIM Guidelines
|
non-achieving HR goals
Patient population will be comprised of typical for cardiological practice sample of patients with Coronary Heart Disease and arterial hypertension administered beta-blockers, subjects non-achieving HR goals, according to ACC/AHA/ACP-ASIM Guidelines
|
- Establish the proportion of patients with stable angina and hypertension on beta-blockers reaching the resting HR goals according to ACC/AHA/ACP-ASIM* Guidelines [ Time Frame: 1 visit within 5 month ]*American College of Cardiology (ACC)/American Heart Association (AHA)/American College of Physicians (ACP-ASIM)
- Establish the mean dose of each beta-blocker in patients who achieved and not achieved resting HR goals [ Time Frame: 1 visit within 5 month ]
- Compare quality of life in patients who achieved and non achieved resting HR goals [ Time Frame: 1 visit within 5 month ]
- To estimate the correlation between achievement of resting HR goals according to ACC/AHA/ACP-ASIM Guidelines for the management of patients [ Time Frame: 1 visits within 5 month ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Stable angina I-III class by the Canadian Cardiovascular Society Classification and concomitant primary hypertension
- Subject is on beta-blockers treatment for at least 2 months prior to inclusion into survey, with no dose change for a minimum of 4 weeks
Exclusion Criteria:
- Use of phenylalkylamine and benzothiazepine calcium channel blockers
- Hemodynamic significant mitral and aortic valve disease
- Acute myocardial infarction and unstable angina within 3 months before enrolment

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01321242
Russian Federation | |
Research Site | |
Ekaterinburg, Russian Federation | |
Research Site | |
Moscow, Russian Federation | |
Research Site | |
Rostov-on-Don, Russian Federation | |
Research Site | |
Saratov, Russian Federation | |
Research Site | |
St.Petersburg, Russian Federation | |
Research Site | |
Ulyanovsk, Russian Federation |
Study Director: | Alexey Stepanov | AstraZeneca | |
Principal Investigator: | Z.D. Kobalava | The Russian Peoples' Friendship University, Municipal Clinical Hospital #64 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT01321242 History of Changes |
Other Study ID Numbers: |
NIS-CRU-ATC-2011/1 |
First Posted: | March 23, 2011 Key Record Dates |
Last Update Posted: | June 1, 2012 |
Last Verified: | May 2012 |
Keywords provided by AstraZeneca:
Resting heart rate Stable Angina Hypertension beta-blockers |
Additional relevant MeSH terms:
Hypertension Angina Pectoris Angina, Stable Vascular Diseases Cardiovascular Diseases Chest Pain Pain Neurologic Manifestations Nervous System Diseases |
Myocardial Ischemia Heart Diseases Signs and Symptoms Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs |